Viewing data from:

LOPERAMIDE HYDROCHLORIDE

ANDA

LOPERAMIDE HYDROCHLORIDE | A215001 | EDENBRIDGE PHARMACEUTICALS LLC

1 strength0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$0.0541

per ea

Lowest NADAC/Unit

$0.0541

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
42799060501LOPERAMIDE 2 MG CAPSULE	$0.0541	EA	Generic	—	2026-06-17
42799060502LOPERAMIDE 2 MG CAPSULE	$0.0541	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 3 NDCs (1 FSS, 2 NC)

Lowest Price

$6.16

Highest Price

$30.19

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
42799-0605-01LOPERAMIDE HCL 2MG CAP	$29.82	FSS	AvKare, LLC	06/14/2028
51407-0999-01LOPERAMIDE HCL 2MG CAP	$6.16	NC	Golden State Medical Supply, Inc.	09/05/2026
51407-0999-05LOPERAMIDE HCL 2MG CAP	$30.19	NC	Golden State Medical Supply, Inc.	09/05/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain6 active DMFs4 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVLOPERAMIDE HYDROCHLORIDE

DMF 73401988

PMC ISOCHEMLOPERAMIDE HYDROCHLORIDE

DMF 74531988

OLON SPALOPERAMIDE HYDROCHLORIDE

DMF 100281992

OLON SPALOPERAMIDE HYDROCHLORIDE

DMF 105171993

VASUDHA PHARMA CHEM LTDLOPERAMIDE HYDROCHLORIDE USP

DMF 277312013

VAMSI LABS LTDLOPERAMIDE HYDROCHLORIDE USP

DMF 425912025

SIFAVITOR SPAInactiveLOPERAMIDE HYDROCHLORIDE

DMF 72991988

SIPSY CHIMIE FINE SCAInactiveLOPERAMIDE HYDROCHLORIDE

DMF 80511989

LANZ LABORATORIESInactiveLOPERAMIDE HYDROCHLORIDE

DMF 83141989

JANSSEN PHARMACEUTICA NVInactiveLOPERAMIDE HYDROCHLORIDE

DMF 109421994

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 2MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Oct 6, 2021

No patent or exclusivity listings for this strength.